Cabinet Decision 592 of 2026: Awards Below Estimated Cost by Up to 20 Percent

1. Key takeaways

Under a KIMADIA announcement of 2026-10-27, Cabinet Decision No. 592 (2026) authorises the Ministry of Health / KIMADIA to accept awards for tenders from reputable specialized foreign manufacturing companies below the estimated cost by less than 20%, as an exception to Article 13(3)(A) of the Government Contracts Implementation Instruction No. 1 (2025), issued pursuant to Article 37(6) of that instruction. This opens a gap in the award threshold of the new 2025 instruction, and it points expressly at foreign manufacturing companies — a substantive benefit for Chinese manufacturers. The recognition criteria for the qualifying phrase have no published definition (see the insights below).

• Decision 592 (2026) authorises MoH / KIMADIA to accept awards below estimated cost by less than 20%.
• The beneficiary class is reputable specialized foreign manufacturing companies.
• The exception is carved out of Article 13(3)(A) of Instruction No. 1 (2025) under the Article 37(6) channel.
• The qualifying adjectives carry no published recognition criteria.

2. Legal basis

The instruments below carry the decision and its legal channel. Verification status follows the source review.

Source-level note. The announcement is an official PDF on the KIMADIA website and is primary and verified; the original of Decision 592 was not obtained on an official domain in this review and is primary but indirectly verified.

Extracts of the operative provisions. The KIMADIA announcement states that KIMADIA announces the issuance of Cabinet Decision No. 592 of 2026, which authorises the Ministry of Health / the State Company for Marketing Drugs and Medical Appliances (KIMADIA) to accept awards for tenders below (20%) of the estimated cost from reputable specialized foreign manufacturing companies, as an exception to the provisions of Article 13(Third)(A) of the Government Contracts Implementation Instruction No. 1 of 2025, and pursuant to Article 37(Sixth) of the said instruction. The official English translation published with the announcement reads: The State Company for Marketing Drugs and Medical Appliances (KIMADIA) announces the issuance of Council of Ministers Decision No. (592) of 2026, which authorizes the Ministry of Health / … (KIMADIA) to accept bids submitted by reputable specialized foreign manufacturing companies at prices below the estimated cost by less than 20%, as an exception to the provisions of Paragraph (13/Third/A) of the Instructions for the Implementation of Government Contracts No. (1) of 2025, pursuant to the provisions of Article (37/Sixth).

Supporting provisions: Article 13(3) sets the 20% threshold against the estimated cost with the handling of exceedance, and paragraph (B) allows a price-negotiation proposal; Article 37(6) allows cabinet exceptions for some government contracts in extreme necessity — the channel of Decision 592; Article 37 also gives domestic products with value addition of no less than 30% meeting the quality specifications a preference, the clause number being unconfirmed in the photocopy.

3. Expert insights

What is torn open is the estimated-cost line. The evaluation committee has a dedicated handling rule for bids deviating 20% from the estimated cost (Article 13(3)), and paragraph (B) allows negotiation to pull the price back into the permitted range. Decision 592 adds an exception channel: for reputable specialized foreign manufacturing companies, awards below the estimated cost within 20% may be accepted. For Chinese manufacturers with structurally lower price offers, the change is from possibly being negotiated out or excluded to being acceptable.

The Arabic formulation admits two readings, and written confirmation is mandatory. The original phrase — below (20%) of the estimated cost — can be read as a price below 20% of the estimated cost, or as below the estimated cost by less than 20%. The price space between the two readings differs enormously. GRZAN’s handling is to confirm the calculation method with KIMADIA in writing before bidding and archive the answer, without pricing on either reading alone.

The qualifying phrase is both the threshold of this case and its blank space. The beneficiary class is limited to reputable specialized foreign manufacturing companies, but no recognition criteria or document list for that status has been seen. GRZAN recommends treating qualification recognition as a pre-communication task: submit manufacturer qualifications, capacity records and reference-country certificates, and seek written recognition before the tender.

In comparison, China prohibits below-cost bidding while Iraq accepts awards somewhat below the estimated cost under specific conditions. Article 33 of China’s Bidding Law expressly bars bidding below cost; the Iraqi decision runs in the opposite direction — under cases of extreme necessity (Article 37(6)) it permits accepting awards below the estimated cost within a margin. The difference in substance: Iraq’s price constraint serves budget executability, not the prevention of low-price competition.

The same instruction also carries the local product preference; the two instruments coexist. Article 37 provides that domestic products with value addition of no less than 30% meeting the quality specifications receive a competitive opportunity. This is not a contradiction but a two-way configuration of policy tools: the benefit to foreign manufacturers flows from a specific exception channel and does not permit the inference that Iraq has relaxed its price threshold.

The official English translation is directly quotable, and it renders the threshold as two undefined adjectives. The two qualifiers — reputable and specialized in the official translation — are given no recognition criteria in the announcement or in Instruction No. 1 of 2025: who assesses, on what materials, and whether advance registration is required are all unstated. For Chinese manufacturers intending to use this channel, this undefined zone is not a crack to slip through but a point that must be confirmed in writing with the tender side before bidding.

4. Practical recommendations

• When GRZAN handles an Iraqi public tender project, the first judgement before pricing is the applicability of Decision 592: confirm whether the contracting entity is the Ministry of Health / KIMADIA and whether the company can be recognised as a reputable specialized foreign manufacturing company.
• Obtain written confirmation from KIMADIA of the calculation method of the 20% and archive it; state the calculation basis relied on in the bid documents.
• Prepare the qualification package for the reputable and specialized status in advance: manufacturer credentials, quality system certificates, reference-country approvals and capacity records. Practical estimate: this list is not published in any official document and is inferred from the announcement wording (no official provision found).
• Do not offset against the local product preference: where a domestic like product with value addition of no less than 30% exists in the tender, assess the application of the preference rule.
• Track the original of Decision 592. As of the verification baseline date it had not been obtained on an official domain, so validity and details follow the KIMADIA announcement retelling; once obtained, re-check the beneficiary scope and validity period.

5. Verification checklist

• □ Connect to the announcement PDF (October 2026 path) and re-check Decision 592 and the 20% threshold.
• □ Search for the original of Decision No. 592 (2026), complete the evidence and check the validity period.
• □ Re-check Article 13(3) of Instruction No. 1 of 2025 and confirm the subject to which the 20% threshold applies.
• □ Re-check the Article 37(6) exception channel and the local product preference (value addition 30%), checking the clause numbers against the gazette pages.
• □ Ask the Ministry of Health / KIMADIA in writing for the recognition criteria and document list for the qualifying status and keep the reply.
• □ Obtain written confirmation of the calculation method of the 20% (the two readings in insight 2).
• □ Re-check whether the official documents cited here have been replaced by later instructions or decisions (verification baseline date: 29 October 2026).

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iraqi market. Our team coordinates local importer arrangements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com